Genetic risk profiles for Alzheimer's disease: Integration of APOE genotype and variants that up-regulate inflammation

Neurobiology of Aging

Volumn 28, Issue 11, 2007, Pages 1637-1643

  Licastro, Federico ^a   Porcellini, Elisa ^a   Caruso, Calogero ^b   Lio, Domenico ^b   Corder, Elizabeth H ^c  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c DUKE UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Cognitive deterioration; Gene polymorphism; GoM analysis; Inflammation

Indexed keywords

AGE DISTRIBUTION; AGED; ALLELE; ALZHEIMER DISEASE; APOE GENE; ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; FUZZY SYSTEM; GENE; GENE CONTROL; GENE FUNCTION; GENE LOCUS; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; INFLAMMATION; INNATE IMMUNITY; ITALY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; UPREGULATION;

AGE FACTORS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEINS E; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK FACTORS; UP-REGULATION; VARIATION (GENETICS);

EID: 34548532090     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2006.07.007     Document Type: Article

References (39)

1. Aisen P.S., Davis K.L., Berg J.D., Schafer K., Campbell K., Thomas R.G., et al. A randomized controlled trial of prednisone in Alzheimer's disease, Alzheimer disease cooperative study. Neurology 54 3 (2000) 588-593
2. Aisen P.S., Shafer K.A., Grundman M., Pfeiffer E., Sano M., Davis K.L., et al. Effects of refecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 289 (2003) 2865-2867
3. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261 (1993) 921-923
4. Corder E.H., Woodbury M.A., Volkmann I., Madsen D.K., Bogdanovic N., and Winblad B. Density profiles of Alzheimer disease regional brain pathology for the Huddinge Brain Bank: pattern recognition emulates and expands upon Braak staging. Exp Gerontol 35 (2000) 851-864
5. Corder E.H., Ervin J.F., Lockhart E., Szymanski M.H., Schmechel D.E., and Hulette C.M. Cardiovascular damage in Alzheimer disease: autopsy findings from the Bryan ADRC. J Biomed Biotechnol 2 (2005) 189-197
6. Corder E.H., Huang R., Cathcart H.M., Lanham I.S., Parker G.R., Cheng D., et al. Membership in genetic groups predicts Alzheimer's disease. Rejuvenation Res 9 1 (2006) 56-60
7. Corder EH, Mellcok GD. Parkinson's disease in relation to toxin exposure and mitochondrial complex I gene variants. J Biomed Biotechnol; 2006 Article ID 27601, 8 pages, 2006, in press.
8. Corder E.H., and Hefler L.A. Multilocus genotypes spanning estrogen metabolism associated with breast cancer and fibroadenoma. Rejuvenation Res 9 (2006) 56-60
9. Folstein M.F., Folstein S.E., and McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 3 (1975) 189-198
10. Franceschi C., Valensin S., Lescai F., Olivieri F., Licastro F., Grimaldi L.M., et al. Neuroinflammation and the genetics of Alzheimer's disease: the search for a pro-inflammatory phenotype. Aging (Milano) 13 (2001) 163-170
11. Grimaldi L.M., Casadei V.M., Ferri C., Veglia F., Licastro F., Annoni G., et al. Association of early-onset Alzheimer's disease with an interleukin-1alpha gene polymorphism. Ann Neurol 47 (2000) 361-365
12. Grimm MO, Grimm HS, Patzold AJ, Zinser EG, Halonen R, Duering M, et al. Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Nat Cell Biol; 2005.
13. in t' Veld B.A., Ruitenberg A., Hofman A., Launer L.J., van Duijn C.M., Stijnen T., et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 345 (2001) 1515-1521
14. Jain M.K., and Ridker P.M. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 4 (2005) 977-987
15. Kajinami K., Akao H., Polisecki E., and Schaefer E.J. Pharmacogenomics of statin responsiveness. Am J Cardiol 96 (2005) 65K-70K [Discussion 34K-35K. Epub October 21, 2005]
16. Lee Y.B., Nagai A., and Kim S.U. Cytokines, chemokines, and cytokine receptors in human microglia. J Neurosci Res 69 (2002) 94-103
17. Licastro F., and Chiappelli M. Brain immune responses cognitive decline and dementia: relationship with phenotype expression and genetic background. Mech Ageing Dev 124 (2003) 539-548
18. Licastro F., Candore G., Lio D., Porcellini E., Colonna-Romano G., Franceschi C., et al. Innate immunity and inflammation in ageing: a key for understanding age-related diseases. Immun Ageing 18 (2005) 2-8
19. Licastro F., Pedrini S., Caputo L., Annoni G., Davis L.J., Ferri C., et al. Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain?. J Neuroimmunol 103 (2000) 97-102
20. Licastro F., Pedrini S., Ferri C., Casadei V., Govoni M., Pession A., et al. Gene polymorphism affecting alpha1-antichymotrypsin and interleukin-1 plasma levels increases Alzheimer's disease risk. Ann Neurol 48 (2000) 388-391
21. Licastro F., Mallory M., Hansen L.A., and Masliah E. Increased levels of alpha-1-antichymotrypsin in brains of patients with Alzheimer's disease correlate with activated astrocytes and are affected by APOE 4 genotype. J Neuroimmunol 88 (1998) 105-110
22. Licastro F., Grimaldi L.M., Bonafe M., Martina C., Olivieri F., Cavallone L., et al. Interleukin-6 gene alleles affect the risk of Alzheimer's disease and levels of the cytokine in blood and brain. Neurobiol Aging 24 (2003) 921-926
23. Licastro F. Genetic background of inflammatory molecules affects protein expression, the risk of developing Alzheimer's disease and cognitive decline. Arch Gerontol Geriatr Suppl 7 (2001) 227-234
24. Licastro F., Chiappelli M., Grimaldi L.M., Morgan K., Kalsheker N., Calabrese E., et al. A new promoter polymorphism in the alpha-1-antichymotrypsin gene is a disease modifier of Alzheimer's disease. Neurobiol Aging 26 (2005) 449-453
25. Licastro F., Pedrini S., Govoni M., Pession A., Ferri C., Annoni G., et al. Apolipoprotein E and alpha-1-antichymotrypsin allele polymorphism in sporadic and familial Alzheimer's disease. Neurosci Lett 270 (1999) 129-132
26. Li G., Higdon R., Kukull W.A., Peskind E., Van Valen Moore K., Tsuang D., et al. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology 63 (2004) 1624-1628
27. Lio D., Licastro F., Scola L., Chiappelli M., Grimaldi L.M., Crivello A., et al. Interleukin-10 promoter polymorphism in sporadic Alzheimer's disease. Genes Immun 4 (2003) 234-238
28. McGeer E.G., and McGeer P.L. The importance of inflammatory mechanisms in Alzheimer disease. Exp Gerontol 33 (1998) 371-378
29. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34 7 (1984) 939-944
30. Morihara T., Teter B., Yang F., Lim G.P., Boudinot S., Boudinot F.D., et al. Ibuprofen suppresses interleukin-1beta induction of pro-amyloidogenic alpha1-antichymotrypsin to ameliorate beta-amyloid (Abeta) pathology in Alzheimer's models. Neuropsychopharmacology 30 (2005) 1111-1120
31. Puglielli L., Tanzi R.E., and Kovacs D.M. Alzheimer's disease: the cholesterol connection. Nat Neurosci 6 (2003) 345-351
32. Reines S.A., Block G.A., Morris J.C., Liu G., Nessly M.L., Lines C.R., et al., Rofecoxib Protocol 091 Study Group. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 62 (2004) 66-71
33. Schmidt R., Schmidt H., Curb J.D., Masaki K., White L.R., and Launer L.J. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol 52 (2002) 168-174
34. Sparks D.L., Sabbagh M.N., Connor D.J., Lopez J., Launer L.J., Browne P., et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 62 (2005) 753-757
35. Sung S., Yang H., Uryu K., Lee E.B., Zhao L., Shineman D., et al. Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer's disease. Am J Pathol 165 (2004) 2197-2206
36. Wolozin B., Kellman W., Ruosseau P., Celesia G.G., and Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57 (2000) 1439-1443
37. Woodbury M.A., and Clive J. Clinical pure types as a fuzzy partition. J Cybernetics 4 (1974) 111-121
38. Zandi P.P., Sparks D.L., Khachaturian A.S., Tschanz J., Norton M., Steinberg M., et al., Cache County Study Investigators. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatr 62 (2005) 217-224
39. Yip A.G., Green R.C., Huyck M., Cupples L.A., Farrer L.A., and MIRAGE Study Group. Nonsteroidal anti-inflammatory drug use and Alzheimer's disease risk: the MIRAGE Study. BMC Geriatr 5 (2005) 2